{"name":"Auspex Pharmaceuticals, Inc.","slug":"auspex-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":37727000,"netIncome":-59574000,"cash":29793000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SD-809","genericName":"SD-809","slug":"sd-809","indication":"Tardive dyskinesia","status":"phase_3"}]}],"pipeline":[{"name":"SD-809","genericName":"SD-809","slug":"sd-809","phase":"phase_3","mechanism":"SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons.","indications":["Tardive dyskinesia","Chorea associated with Huntington's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5sazhaYWNCSl9JeTRVLUhLemNZSENYZTZVVFNiNThNUU5EV0lSN0x1NEJwM1kyR1M3VHBmc1J1NFk3MWFfTDE3bFFkNUlhZzhhUDIxX251cnRpSmtUT195XzhEQXJ4QnhMalIwMnZKOTFtODRT?oc=5","date":"2022-07-21","type":"pipeline","source":"Straits Research","summary":"Brain Health Supplements Market Size, Share, Growth Forecast by 2033 - Straits Research","headline":"Brain Health Supplements Market Size, Share, Growth Forecast by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOdGJVRzd2a2ZLd3c1QU1LaVFJQ0p6VXFrWUhxYVRhR2ZLOXBfZjhvVl90dFVrbENCWUMwNmczbHFjVGpsemR6cUp5cEN1N04yMXRtbTFtWGlsZlU3N0h5V0dPSll6VWZqc1A1bmItNnVCdFltR0c3S0xMd193Y2hiNmQwSU5jS3hsaHVPZ0lQTXNtci1ZVHdFbDZHY9IBVkFVX3lxTE0zRFZyRzBLMUZoRU1fbzRLTlA0b3RnSXNRNDU3OGd3dTdnSGkzYldiWEtZYmlvbkQyeEhIWWVON0FzSHVXM0J1ekp1aWlBWTB6NXg5T09R?oc=5","date":"2022-05-05","type":"pipeline","source":"Law360","summary":"Ex-Pharma CEO To Pay $56K To Settle Insider Trading Case - Law360","headline":"Ex-Pharma CEO To Pay $56K To Settle Insider Trading Case - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNX3NPZm12aVR0dTBoOWR6cnZJcnNTQmU1QmlIcHVHUk1VeWhsdzR6U3pwUXpQVktxTWUwLUlmd1dFOERmYnlPb05Dbk5jQ0VTM0RHNmJLWjN3RW5tRGVYbDFFSzZlUnRHOVM2SFdkUlFMNlNlb2VKY041VXFBTjlkX2syMmdTMVlTMHFxMXUycnBHd3h2cDZfT3V0N0V4NWFpdENfczhOT0VDWEl4Uy1qWEJYS3ZURHdnMHMzVnJvZWg?oc=5","date":"2020-08-25","type":"pipeline","source":"Times of San Diego","summary":"San Diego Biotech Founder Charged with Insider Trading in $3.5 Billion Sale - Times of San Diego","headline":"San Diego Biotech Founder Charged with Insider Trading in $3.5 Billion Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPWkhqWmRWNnVnSWNUVjFaWnR5U1JJLS1NZFk0bHEyLUxNODZPLURHTktabXhGaWRPeDAyVGV3RFB3X1FrNXI5dmp0Uzdvc3U3ekQ3bW1YTXd3NmszeWNxN05rdi1SRzB5Mi05UzJmM0ZiOFBVTlZqTk1uNlVwX08zc0xGUkN1YjJrNkt2dUNUMVA0a05DRl84amR3M2R4S0JFY3hjZFhNNXVDSVo1RTBmV3ZUam9LSnJjU2FsZTVUNlpzenNmdUp3?oc=5","date":"2020-08-25","type":"pipeline","source":"Forbes","summary":"Pharma Founder Charged In Insider Trading Case Over $3.5 Billion Sale To Teva - Forbes","headline":"Pharma Founder Charged In Insider Trading Case Over $3.5 Billion Sale To Teva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPZzdJRjFyWlVwYk82S2cxVjJqNDBwa213RFI3ZVpvWlpXanhNUUdfUGpOZzh0MXFCZl93bHAtUXBpcF9uUC1QUXRLRGRsc0N0dVVMN1NvOWpkWjBRTENRVDVjZ1VIV2NRdEdnNVhzX1VKbUZ3NEI2TE84NU5wakV0M01ZTUVHTHZ0NjFsQ25qdHhLMk9xTE9MV3RncDhOazNCejVv0gGoAUFVX3lxTE5Xd3dJYkhIXzdIdmtZMGcwMmhnM2lHVzBtM0dZc1BnVkxKSEdWRkh5XzZXbTA4MTdYczBibkRwSC1oRlRrMThCXzRmMmNWX2lvNHkxeTRpNWc5Qk0ybTZWc01yZ0VMZWVrY0VkVmlCaWRINjk0aUFWYkI0TEVwbFFEandDQjczbjczZEdOVHk4SmRGMTNKbGF6eVVZYU52QVdXYUo5bXdGNw?oc=5","date":"2020-08-25","type":"pipeline","source":"WVNS","summary":"Ex-pharmaceutical company boss faces insider trading charges - WVNS","headline":"Ex-pharmaceutical company boss faces insider trading charges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE4xbXRfUlZ6bUpLS3RKZ0d2c2FSNVViVHJ2TnF1Zy15QlhFS2k0cUxiUVVNQlhWRmo3V1NXRE5udi1ubDFNa0IwbWJKMFROWjBnbzdyNW9MMmw1WGdfcWFZX0pBZlFndmxXa3NF?oc=5","date":"2016-01-25","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Top 15 M&A Deals of 2015 - Genetic Engineering and Biotechnology News","headline":"Top 15 M&A Deals of 2015","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNbFdfSUtKRi05TVZOOU9BNTNxRDBzamhjSXh5T0c5cFBPNmJXczFPTmdaODMzS2V2ZTRyRGhNMkxnUXR0c3dVVXBZWGZ0VWp2SDk2WlNGdDJBdHpaN3pCTmo4N2p0YTJFamVITnJYd2c2T0JYNjlGeDFGeGRJQnZpdDVJbVdwN2JnYkNJZ0l5TGVPNlRsOHJnUldkc1RTenl5VVplQVdJSS1BVTF1bllqMjJmVnFzSThrSDZTYg?oc=5","date":"2015-05-06","type":"pipeline","source":"European Pharmaceutical Review","summary":"Teva completes acquisition of Auspex; continues pursuit of Mylan - European Pharmaceutical Review","headline":"Teva completes acquisition of Auspex; continues pursuit of Mylan","sentiment":"neutral"},{"date":"2015-05-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNN1dxTEpEVXhGdU85UU1jY2U5aXFYREpMTmhkX2U5VjhxblExLWIwR0RMWmxWNmdGNF9EbmJXdW9zYUJKdG5oV014aEdHUk5oWUM5NnVEdkt1aXRDejRrUE9JTHRGQnNRcUhHano3a01rTmU3SUE5dlUtb1RkdnRHWXhfejZxUTZuajdiX0gxcGRsUDBkWU9sT1N0SHN1NXZMRmMwSUJabERfdmtoUmZpQ0F3X1l5NHpoUmx6Z1VtN1FQUGFWZHh3X3htVDlvdXZHWTFHQ3lINkw?oc=5","date":"2015-03-30","type":"deal","source":"Reuters","summary":"Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion - Reuters","headline":"Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOQWZEOExSWE5NT1FEX3Mtbjg2eFZWSWczQWd2SE1wWURFeXlJeTkzVlZxTHZQcmdNQ1AwMjRXNzlmNDBZN1UzeG05SmdycHhjdXVxWVVPcVZrMjcxVUsxcFNTN2plMWsyeU1sWkd5SkJ6MlhSM3dHbU9QTUNxaWdaZjdySW1OQ1k?oc=5","date":"2014-11-07","type":"deal","source":"San Diego Business Journal","summary":"Executive Q&A: Mike Grey, Venture Partner of Pappas Ventures - San Diego Business Journal","headline":"Executive Q&A: Mike Grey, Venture Partner of Pappas Ventures","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37727000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-59574000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":29793000,"cashHistory":[],"totalAssets":151145000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}